Clinical Trial: Aldara for the Treatment of Extensive Alopecia Areata

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Aldara for the Treatment of Extensive Alopecia Areata

Brief Summary: We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.

Detailed Summary: Ten patients with extensive scalp alopecia areata (>95% hair loss)of less than 2 years duration will be invited to participate in this study. For six months each person will be asked to apply Aldara Cream 5% daily to the right half of the scalp. No drug will be applied to the left side. Skin biopsies will be taken of the right scalp before and at the completion of the therapy.
Sponsor: Hordinsky, Maria K., MD

Current Primary Outcome: To determine the efficacy of Aldara Cream 5% for the treatment of extensive alopecia areata

Original Primary Outcome: Same as current

Current Secondary Outcome: Assess changes in the hair follicle differentiation oand perifollicular inflammation before and after treatment with Aldara Cream5%

Original Secondary Outcome: Same as current

Information By: University of Minnesota - Clinical and Translational Science Institute

Dates:
Date Received: September 9, 2005
Date Started: October 2000
Date Completion: August 2002
Last Updated: November 8, 2006
Last Verified: November 2006